The crucial role of spacer groups in macromolecular prodrug design

Advanced Drug Delivery Reviews

Volumn 21, Issue 2, 1996, Pages 81-106

  Soyez, Heidi ^a   Schacht, Etienne ^a   Vanderkerken, Sylvie ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

cathepsin; cis aconityl; lysosomal enzymes; oligopeptide; prodrugs; spacer; tritosomes

Indexed keywords

CELLS; DRUG THERAPY; ENZYMES; HYDROLYSIS; MACROMOLECULES; MICELLES; ONCOLOGY; PH; POLYMERS;

CATHEPSIN; CIS ACONITYL; LYSOSOMAL ENZYMES; LYSOSOMES; OLIGOPEPTIDE; PRODRUGS; SPACER; TRITOSOMES;

CONTROLLED DRUG DELIVERY;

ANTINEOPLASTIC AGENT; CATHEPSIN B; CATHEPSIN D; COLLAGENASE; COPOLYMER; DAUNORUBICIN; DAUNORUBICIN DERIVATIVE; DOXORUBICIN; DOXORUBICIN DERIVATIVE; DRUG CARRIER; FLUOROURACIL; IBUPROFEN; INSULIN; MACROGOL; MITOMYCIN C; PLASMIN; PLASMINOGEN ACTIVATOR; POLYAMINOACID; POLYGLUTAMIC ACID; POLYMER; POLYSACCHARIDE; PRIMAQUINE; PRODRUG; PROTEIN; PUROMYCIN; UNINDEXED DRUG;

BIODEGRADATION; COVALENT BOND; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG RELEASE; DRUG SOLUBILITY; DRUG TARGETING; HYDROLYSIS; LYSOSOME; MACROMOLECULE; MICELLE; NONHUMAN; PH; PRIORITY JOURNAL; REVIEW; TUMOR;

EID: 0030590499     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(96)00400-0     Document Type: Review

References (148)

1. [1] Waller, D.G. and George, C.F. (1989) Prodrugs. Br. J. Clin. Pharmacol. 28, 497-507.
2. [2] Baldwin, R.W., Byers, V.S. and Mann, R.D. (Eds.) (1990) In: Monoclonal antibodies and immunoconjugates. Parthenon Publishing, Carnforth.
3. [3] Sezaki, H., Takakura, Y. and Hashida, M. (1989) Soluble macromolecular carriers for delivery of antitumor agents. Adv. Drug Deliv. Rev. 3, 247-266.
4. [4] Putnam, D. and Kopecek, J. (1995) Polymer conjugates with anticancer activity. Adv. Polym. Sci. 122, 55-123.
5. [5] Rahman, A. and Schein, P.S. (1988) Use of liposomes in cancer chemotherapy. In: G. Gregoriadis (Ed.), Liposomes as drug carriers. John Willey, New York, pp. 381-400.
6. [6] Gabizon A. (1989) Liposomes as a drug delivery system in cancer chemotherapy. In: F.H.D. Roerdink and A.M. Kroon (Eds.), Drug carrier systems. Vol. 9. John Wiley, New York, pp. 185-212.
7. [7] Brannonpeppas, L. (1995) Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery. Int. J. Pharm. 116, 1-9.
8. [8] Kerr, D.J. and Kaye, S.B. (1991) Chemoembolism in cancer chemotherapy. CRC Crit. Rev. Ther. Drug Carrier Sys. 8, 19-39.
9. [9] Vansavage, G. and Rhodes, C.T. (1995) The sustained release coating of solid dosage forms: a historical review. Drug Dev. Indust. Pharm. 21, 93-118.
10. [10] Yang, M.B., Tamargo, R.J. and Brem, H. (1989) Controlled elivery of 1,3-bis(2-chloroethyl)-1-nitrosourea from ethyl-vinyl acetate copolymer. Cancer Res. 49, 5103-5107.
11. [11] Ringsdorf, H. (1975) Structure and properties of pharmacologically active polymers. J. Polym. Sci.: Polym. Symp. 51, 135-153.
12. [12] Magerstadt, M. (Ed.) (1990) In: Antibody conjugates and malignant disease. CRC Press, Boca Raton.
13. [13] Seymour, L.W. (1994) Soluble polymers for lectin-mediated drug targeting. Adv. Drug Deliv. Rev. 14, 89-111.
14. [14] Fresc, J., Wu, C.H. and Wu, G.Y. (1994) Targeting of genes to the liver with glycoprotein carriers. Adv. Drug Deliv. Rev. 14, 137-152.
15. [15] Schwartz, A. (1991) Trafficking of asialoglycoproteins and the asialoglycoprotein receptor. In: G.Y. Wu and C.H. Wu (Eds.), Liver Diseases. Marcel-Dekker, New York. pp. 3-40.
16. [16] Vansteenkiste, S., Schacht, E. and Seymour, L.W. (1996) Macromolecular carriers for drug targeting. In: C.G. Wermuth (Ed.), The Practice of Medicinal Chemistry. Academic Press Limited, London, pp. 717-736.
17. [17] Wagner, E., Curiel, M. and Gotten, M. (1994) Delivery of drugs, proteins and genes into cells using transferrin as a ligand for receptor-mediated endocytosis. Adv. Drug Deliv. Rev. 14, 113-135.
18. [18] Trowbridge, I.S. and Domingo, D.L. (1981) Antitransferrin receptor monoclonal antibody and toxin antibody conjugates that effect growth of human tumour cells. Nature 294, 171-173.
19. [19] De Smidt, P.C. and Van Berkel, Th.J.C. (1990) LDL-mediated drug targeting. CRC Crit. Rev. Ther. Drug Carrier Sys. 7, 99-120.
20. [20] King, C.R., Kraus, M.H., DiFiorc, P.P. (1990) Implications of erbB-2 overexpression for basic science and clinical medicine. Cancer Biol. 1, 329-337.
21. [21] Robinson, C.J. (1991) Tailoring and targeting fibroblast growth factors. Trends Biotechnol. 9, 147-148.
22. [22] Ghanem, G.E., Comunale, G., Libert, A. (1988) Evidence for alpha-melanocyte stimulating hormone (-MSH) receptors on human malignant melanoma cells. Int. J. Cancer. 41, 248-255.
23. [23] Kwon, G.S. and Kataoka, K. (1995) Block copolymer micelles as long-circulating drug vehicles. Adv. Drug Deliv. Rev. 16, 295-309.
24. [24] Kopecek, J., Rejmanova, P., Duncan, R. and Lloyd, J.B. (1985) Controlled release of drug model from N-(2-hydroxypropyl)methacrylamide copolymers. Ann. NY Acad. Sci. 446, 93-103.
25. [25] Rihova, B., Ulbrich, K., Strohalm, J. Velvicka, V., Bilej, M., Duncan, R. and Kopecek, J. (1989) Biocompatibility of N-(2-hydroxypropyl)methacrylamide copolymers containing adriamycin. Immunogenicity, effect on haematopoietic stem cells in bone marrow in vivo and effect of mouse splenocytes and human peripheral blood lymphocytes in vitro. Biomaterials 10, 335-342.
26. [26] Duncan, R. (1992) Drug-polymer conjugates: potential for improved chemotherapy. Anti-Cancer Drugs. 3, 175-210.
27. [27] Pato, J., Azori, M. and Tudos, F. (1987) Quinidine covalently bound to a dextran carrier. J. Bioact. Biocomp. Polym. 2, 142-147.
28. [28] Mora, M., Pato, J. and Tudos, F. (1989) Polymeric Prodrugs, 6. Synthesis and examination of 6-purinethiol bound to poly(1-vinyl-2-pyrrolidone-co-maleic acid). Makromol. Chem. 190, 1967-1974.
29. [29] Soutif, J.C., Mouity-Moussounda, F. and Brosse, J.C. (1983) Polymeric carriers of glycerol derivatives, 2. Chlorambucil derivatives. Makromol. Chem. Rapid Commun. 4, 61-64.
30. [30] Yasuhiro, M. and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumourotropic accumulation of proteins and the antitumour agent SMANCS. Cancer Res. 46, 6387-6392.
31. [31] Hirano, T., Ringsdorf, H. and Zaharko, D.S. (1980) Antitumour activity of monomeric and polymeric cyclophosphamide derivatives compared with in vitro hydrolysis. Cancer Res. 40, 2263-2267.
32. [32] Przybylski, E., Fell, E., Ringsdorf, H. and Zaharko, D.S. (1978) Pharmacologically active polymers, 17. Synthesis and characterization of polymeric derivatives of the antitumour agent methotrexate. Makromol. Chem. 179, 1719-1733.
33. [33] Remon, J.P., Duncan, R. and Schacht, E. (1984) Polymer-drug combinations: pinocytic uptake of modified polysaccharides containing procainamide moieties by rat visceral yolk sacs cultured in vitro. J. Control. Rel. 1, 47-56.
34. [34] Schacht, E. (1985) Use of polysaccharides as drug carriers. Ann. Natl. Acad. Sci. 446, 199-212.
35. [35] Bernstein, A., Hurwitz, E., Maron, R., Arnon, R., Sela M. and Wilchek, M. (1978) Higher antitumour efficacy of daunomycin when linked to dextran, in vivo and in vitro studies. J. Natl. Cancer Inst. 60, 379-384.
36. [36] Konieezny, M., Charytonowitcz, D. and Inglot, A.D. (1982) Search for carriers for non-covalent binding of interferon among 1,3,5-triazine derivatives of dextran. Arch. Immunol. Ther. Exp. 30, 1-10.
37. [37] Sezaki, H. and Hashida, M. (1984) Macromolecule-drug conjugates in targeted cancer chemotherapy. CRC Crit Rev. Ther. Drug Carrier Syst. 1, 1-38.
38. [38] Matsumoto, S., Yamamoto, A., Takakura, Y., Hashida, M. and Sezaki, H. (1986) Cellular interaction and in vitro antitumour activity of mitomycin C-dextran conjugate. Cancer Res. 46, 4463-4468.
39. [39] Molteni, L. (1979) Dextrans as drug carriers. In: G. Gregoriadis (Ed.), Drug carriers in biology and medicine. Academic Press, London, pp. 107-125.
40. [40] Simonescu, C.R., Popa, M.I. and Dimitriu, S. (1984) Bioactivc polymers. XIV. Immobilization of ampicillin on Biozan R. Naturforsch. 39C, 397-401.
41. [41] Hurwitz, E., Wilchek, M. and Pitha, J. (1980) Soluble macromolecules as drug carriers of daunomycin. J. Appl. Biochem. 2, 25-36.
42. [42] Ouchi, Y., Banba, T., Matsumoto, T., Suzuki, S. and Suzuki, M. (1989) Antitumour activity of chitosan and chitin immobilized 5-fluorouracils through hexamethylene spacers via carbamoyl bonds. J. Bioact. Comp. Polym. 4, 362-371.
43. [43] Ryser, H. and Shen, W.C. (1978) Conjugation of methotrexate to poly(L-lysine) increases drug transport and overcomes drug resistance in cultered cells. Proc. Natl. Acad. Sci. USA. 75, 3867-3870.
44. [44] Zunino, F., Giulliani, F., Savi, G., Dasdia, T. and Gambetta, R. (1982) Antitumour activity of daunorubicin linked to poly(L-aspartic acid). J. Pharmacol. Exp. Ther. 30, 465-469.
45. [45] Giammona, G., Puglisi, G., Carlisi, B., Pignatello, R., Spadaro, A. and Caruso, A. (1989) Polymeric prodrugs:,-poly(N-hydroxyethyl)-DL-aspartamide as macromolecular carrier for some ono-steroidal anti-inflammatory agents. Int. J. Pharm. 57, 55-62.
46. [46] Friedmann, G., Aichaoui, H. and Brini, M. (1981) Polymères à propriétés pharmacologiques potentiels: greffage par liaison amide et (ou) ester d'un hypoglycémiant. Macromol. Chem. 182, 337-347.
47. [47] De Machado, M., Neuse, E.W. and Perlwitz, A.G. (1992) Water-soluble polyamides as potential drug carriers, V. Carboxy-functionalized polyaspartamides and copolyaspartamides. Angew. Makromol. Chem. 195, 35-56.
48. [48] De Marre, A., Soyez, H. and Schacht, E. (1994) Synthesis of macromolecular mitomycin C derivatives. J. Control. Rel. 32, 129-137.
49. [49] Trouet, A., Baurain, R., Deprez-De Campaneere, D., Masquelier, M. and Pierson, P. (1982) Targeting of antitumoral antiprotozoal drugs by covalent linkage to protein carriers. In: G. Gregoriadis, J. Senior and A. Trouet (Eds.), Targeting of drugs. Plenum Press, New York, pp. 19-30.
50. [50] Chu, B.C.F. and Whiteley, J.M. (1979) Control of solid tumour metastasis with a high molecular weight derivative of methotrexate. J. Natl. Cancer Inst. 62, 79-82.
51. [51] Harris J.M. (1992) Introduction to biotechnical and biomedical applications of poly(ethylene glycol). In: J.M. Harris (Ed.). Poly(ethylene glycol) chemistry: biotechnical and biomedical applications. Plenum Press, New York, pp. 1-14.
52. [52] Delgado, C., Francis, G.E. and Fischer, D. (1992) The uses and properlies of PEG-linked proteins. Crit. Rev. Ther. Drug Carrier Sys. 9, 249-304.
53. [53] Abuchowski, A., Kazo, G.M., Verhoest, C.R.Jr, Van Es, T., Kafkewitz, D., Vian, A.T. and Davis, F.F. (1984) Cancer therapy with chemically modified enzymes. I.A property of polyethylene glycol asparaginase conjugates. Cancer Bio. Chem. Biophys. 7, 175-186.
54. [54] Abuchowski, A. and Davis, F.F. (1981) In: J. Hosenberg and J. Roberts (Eds.), Enzymes as drugs. John Wiley and Sons, New York.
55. [55] Cecchi, R., Rusconi, L., Tanzi, M.C., Danusso, F. and Ferruti, P. (1981) Synthesis and pharmacological evaluation of 4-isobutylphenyl-2-propionic acid (Ibuprofen). J. Med. Chem. 2, 622-625.
56. [56] Duncan, R., Kopecek, J. and Lloyd, J.B. (1983) Development of N-(2-hydroxypropyl)methacrylaraide copolymers as carriers of therapeutic agents. In: E. Chiellini and P. Guisti (Eds), Polymers in medicine: Biomedical and pharmacological applications. Vol. 23. Plenum Press, New York, pp. 97-114.
57. [57] Lloyd, J.B., Duncan, R. and Pratten, M.K. (1983) Soluble polymers as targetable agents for intracellular drug release. Br. Polym. J. 15, 158-159.
58. [58] Duncan, R., Kopecek, J., Rejmanova, P. and Lloyd, J.B. (1983) Targeling of N-(2-hydroxypropyl)-methacrylamide copolymers to liver by incorporation of galactose residues. Biochim. Biophys. Acta. 755, 518-521.
59. [59] Seymour, L.W., Flanagan, P.A., Al-Shamkhani, A., Subr, V., Ulbrich, K., Cassidy, J. and Duncan, R. (1991) Synthetic polymers conjugated to monoclonal antibodies: vehicles for tumour-targeted drug delivery. Select. Cancer Ther. 7, 59-73.
60. [60] Flanagan, P.A., Kopeckova, P., Kopecek, J. and Duncan, R. (1992) Evaluation of antibody-N-(2-hydroxypropyl)methacrylamide copolymer conjugates as targetable drug-carriers. 1. Binding, pinocytic uptake and intracellular distribution of transferrin and anti-transferrin receptor antibody-conjugates. Biochim. Biophys. Acta. 993, 83-91.
61. [61] Seymour, L.W., Miyamoto, Y., Maeda, H., Brereton, M., Strohalm, J., Ulbrich, K. and Duncan, R. (1995) Influence of molecular weight on passive tumour accumutation of a soluble macromolecular drug carrier. Eur. J. Cancer. 31A, 766-770.
62. [62] Maeda, H. (1991) SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev. 6, 181-202.
63. [63] Vercauteren, R., Schacht, E. and Duncan, R. (1992) Effect of the chemical modification of dextran on the degradation by rat liver lysosomal enzymes. J. Bioact. Biocomp. Polym. 7, 346-357.
64. [64] Sela, M. and Katachalski, E. (1987) Biological properties of poly(-amino acids). Adv. Protein Chem. 14, 391-478.
65. [65] Mosigny, M., Roche, A.C., Midoux, P. and Mayer, R. (1994) Glycoconjugates as carriers for specific delivery of therapeutic drugs and genes. Adv. Drug Del. Rev., 14, 1-24.
66. [66] Tanaka, H., Satake-Ishakawa, R., Ishakawa, M., Matsuki, S. and Asano, K. (1991) Pharmacokinetics of recombined human granulocyte colony-stimulating factor conjugated to poly(ethylene glycol) in rats. Cancer Res. 51, 3710-3714.
67. [67] Zimmerman, R.J., Aukerman, S.L., Katre, N.V., Winkelhake, J.L. and Young, J.D. (1989) Schedule dependency of antitumour activity and toxicity of poly-(ethylene glycol)-modified interleukin-2 in murine tumour models. Cancer Res. 49, 6521-6528.
68. [68] Ho, D.H.W., Wang, C., Lin, J., Brown, N., Newman, R.A. and Krakoff, I.H. (1988) Polyethylene glycol-L-asparaginase and L-asparaginase studies in rabbits. Drug Metab. Dispos. 16, 27-29.
69. [69] Kurzberg, J., Moore, J.O., Scudiery, D. and franklin, A. (1988) A phase II study of poly(ethylene glycol) (PEG) conjugated L-asparaginase in patients with refractory acute leukaemias. Proc. AACR 29, 213.
70. [70] Yokayama, M., Okano, T., Sakurai, Y., Ekimoto, H., Shibazaki, C. and Kataoka, K. (1991) Toxicity and antitumour activity against solid tumours of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. Cancer Res. 51, 3229-3236.
71. [71] Yokayama, M., Kwon, G.S., Okano, T., Sakurai, Y., Naito, M. and Kataoka, K. (1994) Influencing factors on in vitro micelle stability of adriamycin-block copolymer conjugates. J. Control. Rel. 28, 59-65.
72. [72] Duncan, R. (1987) Selected endocytosis. In: J.R. Robinson and V.H. Lee (Eds.), Controlled drug delivery: fundamentals and applications. Marcel Dekker Inc., New York, pp. 581-621.
73. [73] Gottesman, M.M. (1990) The role of proteases in cancer. Semin. Cancer Biol. 1, 97-160.
74. [74] Connors, T.A. and Knox, R.J. (1995) Prodrugs in cancer chemotherapy. Stem Cells 13, 501-511.
75. [75] Hudecz, F. (1995) Design of synthetic branched-chain polypeptides as carriers for bioactive molecules. Anti-Cancer Drugs 6(2), 171-193.
76. [76] Shen, W.C. and Ryser, H.J.P. (1981) Cis-aconityl spacer between daunomycin and macromolccular carriers: a model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate. Biochem. Biophys. Res. Commun. 102, 1048-1054.
77. [77] Shen, W.C., Ryser, H.J.P. and LaManna, L. (1985) Cleavage of disulfide bonds in endocytosed macromolecules. J. Biol. Chem. 260, 10905-10908.
78. [78] Barrett, A.J. and Heath, M.F. (1972) Lysosomal enzymes. In: J.T. Dingle (Ed.), Lysosomes: a laboratory handbook. North-Holland Publishing Co., Amsterdam, pp. 19-145.
79. [79] Trouet, A. (1974) Methods Enzymol. 31, 323-324.
80. [80] Duncan, R., Cable, H.C., Lloyd, J.B., Rejmanova, P. and Kopecek, J. (1983) Polymers containing enzymatically degradable bonds, 7a) Design of oligopeptide side-chains in poly[N-(2-hydroxypropyl) methacrylamide] copolymers to promote efficient degradation by lysosomal enzymes. Makromol. Chem. 184, 1997-2008.
81. [81] Duncan, R., Rejmanova, P., Kopecek, J. and Lloyd, J.B. (1981) Pinocytic uptake and intracellular degradation of N-(2-hydroxypropyl) methacrylamide copolymers. A potential drug delivery system. Biochem. Biophys. Acta. 678, 143-150.
82. [82] Duncan, R., Rejmanova-Kopeckova, P., Strohalm, J., Hume, I., Cable, H.C., Pohl, J., Lloyd, J.B. and Kopecek, J. (1987) Anticancer agents coupled to N-(2-hydroxypropyl) methacrylamide copolymers. I. Evaluation of daunomycin and puromycin in vitro. Br. J. Cancer. 55, 165-174.
83. [83] Masquelier, M., Baurain, R. and Trouet, A. (1980) Amino acid and oligopeptide derivatives of daunorubicin. 1. Synthesis, physicochemical properties and lysosomal digestion. J. Med. Chem. 23, 1166-1170.
84. [84] Trouet, A., Masquelier, M., Baurain, R. and Deprez-De Campeneere, D. (1982) A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies. Proc. Natl. Sci. USA. 79, 626-629.
85. [85] Duncan, R., Lloyd, J.B. and Kopecek, J. (1980) Degradation of side-chains of N-(2-hydroxypropyl) methacrylamide copolymers by lysosomal enzymes. Biochem. Biophys. Res. Commun. 94, 284-290.
86. [86] Keilova, H. (1970) Inhibition of cathepsin D by diazoacetylnorleucine methyl ester. FEBS Lett. 6, 312-314.
87. [87] Kärgel, H.J., Dettmer, R., Etzold, G., Kirschke, H., Bohley, P. and Langner, J. (1980) Action of cathepsin L on the oxidized B-chain of bovine insulin. FEBS Lett. 114, 257-260.
88. [88] Schechter, I. and Berger, A. (1967) On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun., 27, 157-162.
89. [89] Rejmanova, P., Kopecek, J., Pohl, J., Baudys, M. and Kostka, V. (1983) Polymers containing enzymatically degradable bonds. 8a) Degradation of oligopeptide sequences in N-(2-hydroxypropyl) methacrylamide copolymers by bovine spleen cathepsine B. Makromol. Chem. 184, 2009-2020.
90. [90] Barret, A.J. and Kirschke, H. (1981) Methods Enzymol. 80, 535-561.
91. [91] Subr, V., Kopecek, J., Pohl, J., Baudys, M. and Kosta, V. (1988) Cleavage of oligopeptide side-chains in N-(2-hydroxypropyl) methacrylamide copolymers by mixtures of lysosomal enzymes. J. Control. Rel. 8, 133-140.
92. [92] Kopecek, J. (1984) Controlled biodegradability of polymers - a key to drug delivery systems. Biomaterials 5, 19-25.
93. [93] Subr, V., Strohalm, J., Ulbrich, K., Duncan, R. and Hume, I.C. (1992) Polymers containing enzymatically degradable bonds. XII. Effect of spacer structure on the rate of release of daunomycin and adriamycin from N-(2-hydroxypropyl) methacrylamide copolymer drug carriers in vitro and antitumour activity measured in vivo. J. Control. Rel. 18, 123-132.
94. [94] Duncan, R., Hume, I.C., Yardley, H. J., Flanagan, P.A., Ulbrich, K., Subr, V. and Strohalm, J. (1991) Macromolecular prodrugs for use in targeted cancer chemotherapy: melphalan covalently coupled to N-(2-hydroxypropyl) methacrylamide copolymers. J. Control. Rel. 16, 121-136.
95. [95] Van Heeswijk, W.A.R., Hoes, C.J.T., Stoffer, T., Eenink, M.J.D., Potman, W. and Feijen, J. (1985) The synthesis and characterization of polypeptide-adriamycin conjugates and its complexes with adriamycin Part I. J. Control. Rel. 1, 301-315.
96. [96] Hoes, C.J.T., Potman, W., Van Heeswijk, W.A.R., Mud, J., De Grooth, B.C., Greve, J. and Feijen, J. (1985) Optimization of macromolecular prodrugs of the antitumor antibiotic adriamycin. J. Control. Rel. 2, 205-213.
97. [97] Hoes, C.J.T., Grootoonk, J., Duncan, R., Hume, I.C., Bhakoo, M., Bouma, J.M.W. and Feijen, J. (1993) Biological properties of adriamycin bound to biodegradable polymeric carriers. J. Control. Rel. 23, 37-54.
98. [98] De Marre, A., Seymour, L.W. and Schacht, E. (1994) Evaluation of the hydrolytic and enzymatic stability of macromolecular Mitomycin C derivatives. J. Control. Rel. 31, 89-97.
99. [99] De Marre, A., Soyez, H., Schacht, E., Shoaibi, M.A., Seymour, L.W. and Rihova, B. (1995) Synthesis and evaluation of macromolecular prodrugs of Mitomycin C. J. Control. Rel. 32, 87-97.
100. [100] Soyez, H., De Marre, A. and Schacht, E. (1996) Polymeric prodrugs of Mitomycin C. Macromol. Chem. Symp. Vol., in press.
101. [101] Seymour, L.W., Soyez, H., De Marre, A., Shoaibi, M.A. and Schacht, E. (1996) Improved anticancer efficacy and decreased toxicity for Mitomycin C linked to a soluble synthetic polymer. Anti-Cancer Drug Design, in press.
102. [102] Nichifor, M. and Schacht, E. (1994) Synthesis of peptide derivatives of 5-fluorouracil. Tetrahedron, 50, 3747-3760.
103. [103] Author please supply details for this reference.
104. [104] Nichifor, M., Coessens, V. and Schacht, E. (1995) Macromolecular prodrugs of 5-fluorouracil. 1. Synthesis and hydrolytic stability. J. Bioact. Biocomp. Polym., in press.
105. [105] Nichifor, M., Schacht, E. and Seymour, L.W. (1995) Macromolecular prodrugs of 5-fluorouracil. 2. Enzymatic degradation. J. Control. Rel., in press.
106. [106] De Duve, C. (1959) Lysosomes, a new group of cytoplasmic particles. In: T. Hayashi (Ed.), Subcellular particles. Ronald Press, New York, pp. 128-159.
107. [107] Jain, R.K. and Baxter, L.T. (1988) Mechanisms of heterogenous distribution of monoclonal antibodies and other macromolecules in tumours: significance of elevated interstitial pressure. Cancer Res. 48, 7022-7032.
108. [108] Senior, P.D., Wallace, P.M., Svensson, H.P., Vrudhula, V.M., Kerr, D.E., Hellstrom, I. and Hellstrom, K.E. (1993) Review: generation of cytotoxic agents by targeted enzymes 4, 3-9.
109. [109] Nugent, L.J. and Jain, R.K. (1984) Plasma pharmacokinetics and interstitial diffusion of macromolecules in a capillary bed. Am. J. Physiol. 246, H129-137.
110. [110] Maeda, H. (1992) The tumour vessel as an ideal site for macromolecular anticancer agents. J. Control. Rel. 19, 315-324.
111. [111] Maeda, H. and Matsumura, M. (1989) Tumoritropic and lysosomotropic principles of macromolecular drugs. CRC Crit. Rev. Ther. Drug Carrier Sys. 6, 193-210.
112. [112] Seymour, L.W., Ulbrich, K., Steyger, P.S. Brereton, M., Subr, V., Strohalm, J. and Duncan, R. (1994) Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br. J. Cancer 70, 636-641.
113. [113] Zunino, F., Pratesi, G. and Pezzoni, G. (1987) Increased therapeutic efficacy and reduced toxicity of doxorubicin linked to pyran copolymer via the side chain of the drug. Cancer Treat. Reps. 71, 367-373.
114. [114] Trouet, A. and Jolles, G. (1984) Targeting of daunorubicin by association with DNA or proteins: a review. Rev. Sem. Oncol. 11, 64-73.
115. [115] Seymour, L.W. (1992) Passive tumour targeting of soluble macromolecules and drug conjugates. Crit. Rev. Ther. Drug Carrier Sys. 9, 135-187.
116. [116] Cassidy, J., Duncan, R., Morrison, G.J., Strohalm, J., Plocova, D., Kopecek, J. and Kaye, S.B. (1989) Activity of N-(2-hydroxypropyl) methacrylamide copolymers containing daunomycin against a rat tumour model. Biochem. Pharmacol. 38, 875-880.
117. [117] Vasey, P.A., Duncan, R., Kaye, S.B. and Cassidy, J. (1995) Clinical phase I trial of PK1 (HPMA copolymer-doxorubicin) Eur. J. Cancer 31A, S193.
118. [118] Liotta, L.A., Rao, N.C. and Wever, U.M. (1986) Biochemical interactions of tumor cells with basement membrane. Ann. Rev. Biochem. 55, 1037-1057.
119. [119] Tryggvason, K., Hoyhtya, M. and Saho, M. (1987) Proteolytic degradation of extracellular matrix in tumor invasion. Biochim. Biophys. Acta. 907, 191-217.
120. [120] Canete-Soler, R., Litzky, L., Lubesky, I. and Muschel, R.J. (1994) Localization of the 92kD gelatinase mRNA in squamous cell and adenocarcinomas of the lung using in situ hybridization. Am. J. Pathol. 144, 518-527.
121. [121] Naylor, M.S., Stamp, G.W., Davies, B.D. and Balkwill, F.R. (1994) Expression and activity of MMPs and their regulators in ovarian cancer. Int. J. Cancer 58, 50-56.
122. [122] David, L., Nesland, J.M., Holm, R. and Sobrinho-Simoes, M. (1994) Expression of laminin, collagen IV, fibronectin and type IV collagenase in gastric carcinoma. Cancer 73, 518-527.
123. [123] Milburn Jessup J. (1994) Cathepsin B and other proteases in human colorectal carcinoma. Am. J. Pathol. 145, 253-262.
124. [124] Campo, E., Munoz, J., Miquel, R., Palacin, A., Cardesa, A., Sloane, B.F. and Emmert-Buck, M.R. (1994) Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. Am. J. Pathol. 145, 301-309.
125. [125] Weber, E., Günther, D., Laube, F., Wiederanders, B. and Kirschke, H. (1994) Hybridoma cells producing antibodies to cathepsin L have greatly reduced potential for growth. J. Cancer Res. Clin. Oncol. 120, 564-567.
126. [126] Liaudet, E., Garcia, M. and Rochefort, H. (1994) Cathepsin D maturation and its stimulatory effect on metastasis are prevented by addition of KDEL retention signal. Oncogene 9, 1145-1154.
127. [127] Funahashi, T., Shimamura, M., Kocha, T., Fukuda, T. and Aoyagi, T. (1994) Proportionality of protease activities in malignant cells to their metastatic potential. Biol. Pharm. Bull. 17, 1118-1120.
128. [128] Moser, T.L., Young, T.N., Rodriguez, G.C., Pizzo, V.S., Bast, R.C. and Stack M.S. (1994) Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int. J. Cancer 56, 552-559.
129. [129] Vassalli, J.-D. and Pepper, M.S. (1994) Membrane proteases in focus. Nature 370, 14-16.
130. [130] Yamashita, J.I., Ogawa, M., Ikei, S., Omachi, H., Yamashita, S.-I., Saishoji, T., Nomura, K. and Sato, H. Production of immunoreactive polymorphonuclear leucocyte elastase in human breast cancer cells: possible role of polymorphonuclear leucocyte elastase in human breast cancer. Br. J. Cancer 69, 72-76.
131. [131] Uria, J.A., Ferrando, A.A., Velasco, G., Freije, J.M.P. and López-Otin, C. (1994) Structure and expression in breast tumors of human TIMP-3, a new member of the metalloprotease inhibitor family. Cancer Res. 54, 2091-2094.
132. [132] Visscher, D.W., Hoyhtya, M., Ottosen, S.K., Liang, C.-M., Sarkar, F.H., Crissman, J.D. and Fridman, R. (1994) Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int. J. Cancer 59, 339-344.
133. [133] Duffy, M.J. (1993) Urokinase-type plasminogen activator and malignancy. Fibrinolysis 7, 295-302.
134. [134] Mignatti, P. and Rifkin, D.B. (1993) Biology and biochemistry of proteinases in tumor invasion. Physicol. Rev. 73(1), 161-187.
135. [135] Chakravarty, P.K., Philip, L.C., Weber, M.J. and Katzenellenbogen, J.A. (1983) Plasmin-activated prodrugs for cancer chemotherapy. 1. Synthesis and biological activity of peptidylacivicin and peptidylphenylenediamine mustard. J. Med. Chem. 26, 633-638.
136. [136] Chakravarty, P.K., Philip, L.C., Weber, M.J. and Katzenellenbogen, J.A. (1983) Plasmin-activated prodrugs for cancer chemotherapy. 1. Synthesis and biological activity of peptidyl derivatives of doxorubicin. J. Med. Chem. 26, 638-644.
137. [137] Boag, A.M. and Young I.D. (1994) Increased expression of the 72-kD type IV collagenase in prostatic adenocarcinoma. Am. J. Pathol. 144, 585-591.
138. [138] Stack, M.S. and Gray, R.D. (1989) Comparison of vertebrate collagenase and gelatinase using fluorogenic substrate peptide. J. Biol. Chem. 264, 4277-4281.
139. [139] Bode, W., Reinemer, P., Huber, R., Kleine, T., Schniere, S. and Tschesche, H. (1994) The X-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. EMBO J. 13, 1263-1269.
140. [140] Nagase, H., Fields, C.G. and Fields, G.B. (1994) Design and characterization of a fluorogenic substrate selectively hydrolyzed by stromelysin 1 (MMP-3). J. Biol. Chem. 269, 20 952-20 957.
141. [141] Marquisee, M.J. and Kauer, J.C. (1978) Collagenase-sensitive peptidyl-nitrogen mustards as potential antitumor agents. J. Med. Chem. 21, 1188-1194.
142. [142] Ohta, T., Terenda, T., Nagakawa, T., Tajima, H., Itoh, L., Fonseca, L. and Miyazaki, I. (1994) Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and associated metastasis. Br. J. Cancer 69, 152-156.
143. [143] Buck, M.R., Karustis, D.G., Day, N.A., Honn, K.V. and Sloane, B.F. (1992) Degradation of extracellular matrix proteinases by human cathepsin B from normal and tumor tissues. Biochem. J. 282, 273-278.
144. [144] Kobayashi, H., Schmitt, M., Goretzki, L., Chucholowski, N., Calvete, J., Kramer, M., Guntzler, W.A., Janicke, F. and Graeff, H. (1991) Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator. J. Biol. Chem. 266, 5147-5152.
145. [145] Press, E.M., Porter, R.R. and Cebra, J. (1960) The isolation and properties of a proteolytic enzyme, cathepsin D, from bovine spleen. Biochem. J. 74, 501-514.
146. [146] Keilova, H. and Keil, B. (1968) On proteins. CXIII. Specificity of cleavage of heptapeptide substrate with bovine spleen cathepsin D. Coll. Czech. Chem. Comm. 33, 131-140.
147. [147] Ferguson, J.B., Andrews, J.R., Voynick, I.M. and Fruton, J.S. (1973) The specificity of cathepsin D. J. Biol. Chem. 18, 6701-6708.
148. [148] Kazakova, O.V. and Orekhovich, V.N. (1972) Effect of cathepsins D from normal and malignant tissues on synthetic peptides. J. Biol. Chem. 247, 4224-4228.